ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO496

Health State Utility Values for Immunoglobulin A Nephropathy (IgAN)

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials

Authors

  • Zhou, Mo, Analysis Group Inc Boston, Boston, Massachusetts, United States
  • Bensink, Mark Eliot, Travere Therapeutics Inc, San Diego, California, United States
  • Hazra, Nisha C., Analysis Group Inc, London, United Kingdom
  • Xu, Chunyi, Analysis Group Inc Boston, Boston, Massachusetts, United States
  • Hendry, Bruce M., Travere Therapeutics Inc, San Diego, California, United States
  • Sharpe, Claire C., Wilkins and Sharpe Ltd., London, United Kingdom
  • Zhou, Zheng-Yi, Analysis Group Inc, London, United Kingdom
Background

IgAN has been shown to be associated with significant clinical burden to patients with progression to kidney failure resulting in reduced health-related quality of life (HRQL). Utility values are a preference-based measure quantifying the HRQL of a disease. To date, no studies have reported utility values specifically for IgAN. The objective of this study was to estimate utility values for the spectrum of health states related to IgAN from the societal perspective in the UK.

Methods

Utilities for IgAN were elicited from the UK general public via computer-assisted telephone interviews. Respondents were shown written vignettes describing several health states for IgAN with different chronic kidney disease (CKD) stages, proteinuria levels, and dialysis status, and for a health state with nephrotic syndrome. Vignettes were validated by five nephrologists experienced in treating IgAN in the UK. Time tradeoff (TTO) was used to estimate utilities. For each health state, the moderator assessed the number of years in an imperfect health state a respondent was willing to give up to live in full health. The utilities for the health states, ranging from –1 (worse than death) to +1 (perfect health), were calculated based on responses. TTO utilities were validated with Visual Analogue Scale (VAS) ratings.

Results

TTO-derived utilities (n=200) decreased as IgAN-associated CKD/proteinuria severity increased: mean (SD) CKD stage 1/2, 0.84 (0.17) and 0.71 (0.23); CKD stage 3, 0.68 (0.23) and 0.61 (0.25); CKD stage 4, 0.55 (0.26) and 0.49 (0.27) for proteinuria <1g/day and proteinuria ≥1g/day, respectively. Within a CKD stage, utilities associated with proteinuria ≥1g/day were 0.06-0.13 lower than those with proteinuria <1g/day (p<0.001), with mean decrement of 0.09. The mean (SD) utility for CKD stage 5 with and without dialysis was 0.38 (0.30) and 0.42 (0.28), respectively (p<0.001). The mean (SD) utility for nephrotic syndrome was 0.43 (0.33). VAS and TTO results were consistent.

Conclusion

Utilities decreased with IgAN CKD stage progression and increased proteinuria. Treatments that reduce proteinuria and slow the rate of decline in kidney function have the potential to improve the HRQL of patients with IgAN.

Funding

  • Commercial Support